LPA2 antagonist 2

Research use only, not for human use.

LPA2 antagonist 2 is a selective and potent LPA2 antagonist (IC50: 28.3 nM) with potential anticancer activity, inhibits LPA3, and can be used in the study of cancer.

LPA2 antagonist 2 (H2L 5226501) is a selective LPA2 antagonist with an IC50 of 28.3 nM and a Ki of 21.1 nM. LPA2 antagonist 2 is >480-fold more selective than LPA3 (IC50 of 13.85 μM).

Lysophosphatidic acid (LPA) is a phospholipid mediator that elicits a host of biological effects including cell proliferation, survival, motility and differentiation. LPA has been shown to regulate cancer cell invasion, metastasis, and resistance to both chemotherapeutics and radiation. LPA2 antagonist 2 (H2L 5226501) inhibits LPA1 with an Imax of 59.0% at 30 μM.

——

——

GPCR/G Protein

LPA Receptor

LPA Receptor

——

——

36840-10-5

380.35

C20H16N2O6

>98% (HPLC)

In Vitro:?DMSO : 83.33 mg/mL (219.09 mM; Ultrasonic )

O=C(O)C=CC(=O)NC=1C=CC(=CC1)C2=CC=C(C=C2)NC(=O)C=CC(=O)O

——

(-20℃)

With Ice Pack

≥ 2 years